Patents by Inventor Dominic Cliché

Dominic Cliché has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of Antisense Oligonucleotides or siRNA to Suppress Expression of eIF-5A1
    Publication number: 20130066058
    Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.
    Type: Application
    Filed: August 10, 2012
    Publication date: March 14, 2013
    Inventors: John E. Thompson, Bruce C. Galton, Catherine Taylor, Adrienne Boone, Elizabeth Margaret Heikkila, Dominic Cliche, Shelley Culp-Stewart, John Gerard Flannagan, Michelle Senchyna
  • siRNA useful to supress expression of EIF-5A1
    Patent number: 8242256
    Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: August 14, 2012
    Assignee: Senesco Technologies, Inc.
    Inventors: John E. Thompson, Bruce C. Galton, Catherine Taylor, Adrienne Boone, Elizabeth Heikkila, Dominic Cliche, Shelley Culp-Stewart, John Gerard Flanagan, Michelle Senchyna
  • Nucleic Acids, Polypeptides, Compositions, and Methods for Modulating Apoptosis
    Publication number: 20120064625
    Abstract: The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific eIF-5A and DHS useful in such methods.
    Type: Application
    Filed: January 14, 2011
    Publication date: March 15, 2012
    Inventors: Catherine Taylor, Tzann-Wei Wang, Larry Petrov, John C. Carlson, Richard Narayansingh, Marianne Kaup, Dominic Cliche, John E. Thompson
  • SiRNA Useful to Suppress expression of eIF-5A1
    Publication number: 20110098460
    Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.
    Type: Application
    Filed: December 17, 2009
    Publication date: April 28, 2011
    Applicant: Senesco Technologies, Inc.
    Inventors: John E. Thompson, Bruce C. Galton, Catherine Taylor, Adrienne Boone, Elizabeth Heikkila, Dominic Cliche, Shelley Culp-Stewart, John Gerard Flanagan, Michelle Senchyna
  • Expression vector encoding apoptosis-specific eIF-5A
    Patent number: 7872112
    Abstract: The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific eIF-5A and DHS useful in such methods.
    Type: Grant
    Filed: November 13, 2006
    Date of Patent: January 18, 2011
    Assignee: Senesco Technologies, Inc.
    Inventors: Catherine A. Taylor, Tzann-Wei Wang, Larry Petrov, John C. Carlson, Richard Narayansingh, Marianne Kaup, Dominic Cliche, John E. Thompson
  • Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
    Patent number: 7662796
    Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.
    Type: Grant
    Filed: November 28, 2005
    Date of Patent: February 16, 2010
    Assignee: Senesco Technologies, Inc.
    Inventors: John E. Thompson, Bruce C. Galton, Catherine Taylor, Adrienne Boone, Elizabeth Heikkila, Dominic Cliche, Shelley Culp-Stewart, John Gerard Flanagan, Michelle Senchyna
  • Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye
    Patent number: 7381708
    Abstract: The present invention provides methods for preventing retinal ganglion cell death in the glaucomatous eye and methods for suppressing apoptosis-specific eIF5A1 expression through the use of antisense oligonucleotides targeted to human apoptosis-specific eIF5A1.
    Type: Grant
    Filed: March 10, 2003
    Date of Patent: June 3, 2008
    Assignee: Sensco Technologies, Inc.
    Inventors: Catherine Taylor, Dominic Cliché, Elizabeth Margaret Heikkila, Diane Michelle Senchyna, John Gerard Flanagan, John E. Thompson
  • Nucleic acids, polypeptides, and methods for modulating apoptosis
    Patent number: 7217517
    Abstract: The present invention provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of reducing apoptosis in mammalian tissue, preferably heart tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5a is higher than proliferating eIF-5A. In the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A. Preferred agents are antisense oligonucleotides to human apoptosis-specific eIF-5A.
    Type: Grant
    Filed: October 23, 2002
    Date of Patent: May 15, 2007
    Assignee: Senesco Technologies, Inc.
    Inventors: John E. Thompson, Catherine Taylor, Dominic Cliche, Charles Dinarello, Leonid Reznikov, Benjamin Pomerantz
  • Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
    Publication number: 20070059831
    Abstract: The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific eIF-5A and DHS useful in such methods.
    Type: Application
    Filed: November 13, 2006
    Publication date: March 15, 2007
    Applicant: Senesco Technologies, Inc.
    Inventors: Catherine Taylor, Tzann-Wei Wang, Larry Petrov, John Carlson, Richard Narayansingh, Marianne Kaup, Dominic Cliche, John Thompson
  • Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
    Patent number: 7166467
    Abstract: The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific eIF-5A and DHS useful in such methods.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: January 23, 2007
    Assignee: Senesco Technologies, Inc.
    Inventors: Catherine Taylor, Tzann-Wei Wang, Larry Petrov, John C. Carlson, Richard Narayansingh, Marianne Kaup, Dominic Cliche, John E. Thompson
  • Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
    Publication number: 20060178330
    Abstract: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis factor 5A1 or simply factor 5A1, apoptosis factor 5A1 nucleic acids and polypeptides and methods for inhibiting or suppressing apoptosis in cells using antisense nucleotides or siRNAs to inhibit expression of factor 5A1. The invention also relates to suppressing or inhibiting expression of pro-inflammatory cytokines by inhibiting expression of apoptosis factor 5A.
    Type: Application
    Filed: November 28, 2005
    Publication date: August 10, 2006
    Applicant: Senesco Technologies, Inc.
    Inventors: John Thompson, Bruce Galton, Catherine Taylor, Adrienne Boone, Elizabeth Helkkila, Dominic Cliche, Shelley Culp-Stewart, John Flanagan, Michelle Senchyna
  • Suppression of eIF5A1 expression to prevent retinal ganglion cell death in the glaucomatous eye
    Publication number: 20030225022
    Abstract: The present invention provides methods for preventing retinal ganglion cell death in the glaucomatous eye and methods for suppressing apoptosis-specific eIF5A1 expression through the use of antisense oligonucleotides targeted to human apoptosis-specific eIfF5A1.
    Type: Application
    Filed: March 10, 2003
    Publication date: December 4, 2003
    Inventors: Catherine Taylor, Dominic Cliche, Elizabeth Margaret Heikkila, Diane Michelle Senchyna, John Gerard Flanagan, John E. Thompson
  • Nucleic acids, polypeptides, and methods for modulating apoptosis
    Publication number: 20030144238
    Abstract: The present invention provides methods of identifying an incidence of ischemia in mammalian tissue, particularly mammalian heart tissue. Further, a method of reducing apoptosis in mammalian tissue, preferably heat tissue, is provided. These methods involve measuring and comparing the gene expression levels of both apoptosis-specific eIF-5A and proliferating eIF-5A and correlating an incidence of ischemia when the expression level of apoptosis-specific eIF-5a is higher than proliferating eIF-5A. In the method of reducing apoptosis in mammalian tissue, there is provided an agent that inhibits expression of apoptosis-specific eIF-5A. Preferred agents are antisense oligonucleotides to human apoptosis-specific eIF-5A.
    Type: Application
    Filed: October 23, 2002
    Publication date: July 31, 2003
    Inventors: John E. Thompson, Catherine Taylor, Dominic Cliche, Charles Dinarello, Leonid Reznikov, Benjamin Pomerantz
  • Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
    Publication number: 20030064952
    Abstract: The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific eIF-5A and DHS useful in such methods.
    Type: Application
    Filed: May 7, 2002
    Publication date: April 3, 2003
    Inventors: Catherine Taylor, Tzann-Wei Wang, Larry Petrov, John C. Carlson, Richard Narayansingh, Marianne Kaup, Dominic Cliche, John E. Thompson